- Founding partner sees ‘golden-era of innovation’
- Firm raised $200m for debut fund
- Fund I has notched three exits via IPO and two via M&A
ORI Capital, a biotech investor based in Hong Kong, has closed its second fund at $260 million.
“We are in a golden-era of innovation across the intersection of AI and biology, where technological breakthroughs are creating new approaches to diagnosing and treating disease,” founding partner Simone Song said in a statement. “We believe the current environment provides an attractive opportunity for investing in the next generation of leading biotech companies.”
ORI focuses on “growth-oriented venture investments in biotech sector specifically targeting early to early to mid-stage life sciences companies developing novel therapeutics in addition to life sciences tools and diagnostics companies,” the firm said in the statement. I noted that its exits include three via IPOs, CG Oncology, Orchard Therapeutics and TriSalus Life Sciences, and two via acquisitions, Kymab and Semma Therapeutics.
Founded in 2015, ORI closed on $200 million for its debut fund in January 2018, according to fundraising data from affiliate Private Equity International (registration required). The firm did not disclose the names of LPs in either of its funds, but PEI reported that Fund I investors include Shenzhen Hepalink Pharmaceutical, a Chinese company that committed $20 million.
